1月14日晚间，证监会、上交所接连出手。 证监会：对向日葵立案调查 1月14日晚间，据证监会公告，2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披 露重组预案。近期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发 现重组预案涉嫌误导性陈述，已于近日对向日葵立案调查。下一步，将在全面调查的基础上依法处理， 切实维护并购重组市场秩序。 上交所：暂停国晟科技部分投资者账户交易 1月14日晚间，上交所发布关于国晟科技相关情况的通报，国晟科技近期多次出现异常波动情形，公司 已多次发布风险提示公告，提请广大投资者审慎投资，注意投资风险。近日，该股股价继续大幅波动， 部分投资者在交易该股过程中存在影响股票交易正常秩序的异常交易行为，上交所依规对相关投资者采 取了暂停账户交易等自律监管措施。上交所再次提醒投资者关注风险，审慎参与，合规交易。 同日晚间，国晟科技也公告称，公司股票连续三个交易日内收盘价格涨幅偏离值累计超过20%，属于股 票交易异常波动情况。2025年10月31日至2026年1月14日期间，公司股票6次触及股价异常波动、1次触 及严重异常波动情形，期间累计涨幅高达5 ...

证监会1月14日消息，浙江证监局对向日葵（300111）重组预案涉嫌误导性陈述立案调查。 2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组预案。近期，重组标的 的实际产能和业务模式引发市场质疑，浙江证监局依法开展核查工作，发现重组预案涉嫌误导性陈述， 已于近日对向日葵立案调查。下一步，将在全面调查的基础上依法处理，切实维护并购重组市场秩序。 ...

向日葵重组再生枝节！兮璞材料隐蔽关联交易 被骗了？A股上市公司跨界重组"踩雷" 据证监会官网， 浙江证监局对向日葵重组预案涉嫌误导性陈述立案调查。 2025年9月22日， 浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组预案。近期，重组标的的实际产能和业务模式引发市场质疑， 浙江 证监局依法开展核查工作，发现重组预案涉嫌误导性陈述，已于近日对向日葵立案调查。 下一步，将在全面调查的基础上依法处理，切实维护并购 重组市场秩序。 此前，财联社曾多次刊发涉及向日葵重组相关报道，相关文章如下： ...

2025年9月22日，浙江向日葵大健康科技股份有限公司（简称向日葵）披露重组 预案。近期，重组标的的实际产能和业务模式引发市场质疑，浙江证监局依法开展核 查工作，发现重组预案涉嫌误导性陈述，已于近日对向日葵立案调查。下一步，将在 全面调查的基础上依法处理，切实维护并购重组市场秩序。 ...

一桩桩逐级加价的电子氟化液大宗交易，当初只是感觉有点蹊跷，但经过财联社记者深入采访和调查，却发现原来是一笔笔精心编织的隐蔽 关联交易。 其中的关键角色，是上海亚格兴新材料有限公司（简称"上海亚格兴"），其唯一股东是张敏，也是公司法定代表人，他正是向日葵 （300111.SZ）重组标的——漳州兮璞材料科技有限公司（简称"兮璞材料"）董事长张琴的父亲。 由于向日葵至今未披露回复深交所关注函的具体内容，公众无从知晓其向监管部门提供的材料是否真实、准确、完整。 这对投资者而言， 是一种信息不对称。也导致多个"有模有样"的所谓关注函书面回复材料，在股吧、论坛等渠道广泛传播。公司既不承认，也不否认，真假难 辨，进一步加大了信息的混乱和股价的波动。 涉及上市公司重组的重要信息，事关公众利益，又非商业机密，公开，才是应有的选择。 财联社2025年12月25日发表的 《兮璞材料"抢跑"上市 向日葵跨界半导体"暗礁"隐现》 的报道，揭露了兮璞材料异常的电子氟化液交易， 以及核心产能未落地、半导体资产成色不足的事实。 深交所在报道发布的翌日凌晨下发关注函，要求向日葵核实文章涉及的四个方面的问题，同时要求独立财务顾问发表明确意见，其 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 转自：天眼查 智通财经1月14日讯（记者 张校毓 陆婷婷 刘建 徐学成）一桩桩逐级加价的电子氟化液大宗交易，当初只是感觉有点蹊 跷，但经过智通财经记者深入采访和调查，却发现原来是一笔笔精心编织的隐蔽关联交易。 其中的关键角色，是上海亚格兴新材料有限公司（简称"上海亚格兴"），其唯一股东是张敏，也是公司法定代表人， 他正是向日葵（300111.SZ）重组标的——漳州兮璞材料科技有限公司（简称"兮璞材料"）董事长张琴的父亲。 由于向日葵至今未披露回复深交所关注函的具体内容，公众无从知晓其向监管部门提供的材料是否真实、准确、完 整。这对投资者而言，是一种信息不对称。也导致多个"有模有样"的所谓关注函书面回复材料，在股吧、论坛等渠道 广泛传播。公司既不承认，也不否认，真假难辨，进一步加大了信息的混乱和股价的波动。 涉及上市公司重组的重要信息，事关公众利益，又非商业机密，公开，才是应有的选择。 智通财经2025年12月25日发表的《兮璞材料"抢跑"上市 向日葵跨界半导体"暗礁"隐现》的报道，揭露了兮璞材料异常 的电子氟化液交易，以及核心产能未落地、半导体资产成色不足的事 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300111 | 向日葵 | 7.29 | 11.98% | 167.84万 | | 11.97亿 | | 000766 | 通化金马 | 27.87 | 9.98% | 46.86万 | | 12.97亿 | | 002940 | 昂利康 | 38.66 | 7.87% | 25.79万 | | 9.79亿 | | 300401 | 化园生物 | 17.36 | 5.60% | - 54.32万 | | 2666 | | 920367 | 新赣江 | 23.50 | 5.48% | 5.45万 | | 1.26亿 | | 688176 | 亚虹医药 | 12.60 | 5.09% | 19.90万 | | 2.45亿 | | 301281 | 科源制药 | 30.83 | 5.08% | 4.03万 | | 1.22亿 | | 000908 | *ST景峰 | 8.19 | 5.00% | 3.17万 | | 2599.61万 | ...

Group 1 - The core viewpoint of the news is that Sunflower has shown fluctuations in its stock price and financial performance, with a recent increase in stock price but a decline in revenue and profit [1][2]. - As of January 8, Sunflower's stock price increased by 2.03% to 6.52 CNY per share, with a total market capitalization of 8.393 billion CNY [1]. - The company has experienced a net outflow of main funds amounting to 2.1356 million CNY, while large orders showed mixed buying and selling activity [1]. Group 2 - For the period from January to September 2025, Sunflower reported a revenue of 200 million CNY, a year-on-year decrease of 12.09%, and a net profit attributable to shareholders of 1.3062 million CNY, down 53.10% year-on-year [2]. - The company has a total of 133,000 shareholders as of September 30, which is an increase of 112.98% compared to the previous period, while the average circulating shares per person decreased by 53.05% to 9,676 shares [2]. - Since its A-share listing, Sunflower has distributed a total of 204 million CNY in dividends, with no dividends paid in the last three years [3].

Group 1 - The core viewpoint of the news is that Sunflower's stock has experienced a decline in recent trading sessions, with a notable drop of 2.03% on January 7, leading to a market capitalization of 8.058 billion yuan [1] - As of January 7, the stock price is reported at 6.26 yuan per share, with a trading volume of 119 million yuan and a turnover rate of 1.45% [1] - The net outflow of main funds is 21.7157 million yuan, with significant selling pressure observed, as large orders sold 25.2535 million yuan, accounting for 21.29% of the total [1] Group 2 - Year-to-date, Sunflower's stock price has increased by 2.12%, but it has seen a decline of 2.03% over the last five trading days, 16.64% over the last 20 days, and 8.08% over the last 60 days [2] - Sunflower, established on March 21, 2005, and listed on August 27, 2010, focuses on the pharmaceutical sector, primarily in the research, production, and sales of anti-infection, cardiovascular, and digestive system drugs [2] - The company's revenue composition includes 73.44% from raw materials, 26.37% from formulated drugs, and 0.19% from other (non-main) sources [2] Group 3 - Sunflower has distributed a total of 204 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3]

Market Overview - The chemical pharmaceutical sector experienced a decline of 0.49% on December 26, with Sunflower leading the drop [1] - The Shanghai Composite Index closed at 3963.68, up 0.1%, while the Shenzhen Component Index closed at 13603.89, up 0.54% [1] Stock Performance - Notable gainers included: - Hongyuan Pharmaceutical (301246) with a closing price of 26.88, up 20.00% and a trading volume of 476,800 shares, totaling 1.216 billion yuan [1] - Fuxiang Pharmaceutical (300497) closed at 16.08, up 6.70% with a trading volume of 889,200 shares, totaling 1.4 billion yuan [1] - Key stocks with positive performance also included Keyuan Pharmaceutical (301281), Kangzhiyue Pharmaceutical (300086), and Ailisi (688578) [1] - Major decliners included: - Sunflower (300111) with a closing price of 6.36, down 10.80% and a trading volume of 1,429,900 shares, totaling 899 million yuan [2] - Xinnoway (300765) closed at 36.88, down 6.77% with a trading volume of 189,500 shares, totaling 711 million yuan [2] - Other notable declines were seen in Shouyao Holdings (688197) and Kelun Pharmaceutical (002422) [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 1.096 billion yuan from institutional investors, while retail investors contributed a net inflow of 914 million yuan [2] - The capital flow data indicates that: - Hongyuan Pharmaceutical had a net inflow of 230 million yuan from institutional investors, while retail investors had a net outflow of 127 million yuan [3] - Fuxiang Pharmaceutical experienced a net inflow of 178 million yuan from institutional investors, with a net outflow of 140 million yuan from retail investors [3] - Other companies like Shutaishen (300204) and Kangzhiyue (300086) also showed varied capital flows [3]